A Phase 2 interventional study of Placebo and Ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, sponsored by Genentech, Inc.. Completed at 84 sites in 18 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-12-31.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting — 2 open to participants now, 5 under way, 3 of them phase 3. ocrelizumab · Multiple Sclerosis, Relapsing-Remitting.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, this one is the 7th largest by enrollment, is the only one that started in 2008, is the only one in phase 2, and was the 1st registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting are open now, in 2 countries. Recruiting first, the newest first:
Celltrion · Sites in Poland
Ages 18–55
University of California, San Francisco · Sites in United States
Ages 18–65
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2008.
This study's enrollment of 220 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 404 across the 10 interventional studies. Of the 5 that completed or were terminated, 5 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche: 2 open now, 5 under way, 2 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 2, and was the 2nd registered.
Hoffmann-La Roche’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2004.
3 of the studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05906992Phase 3CelltrionA Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | 2027-02 |
| NCT05296161Amsterdam UMC, location VUmcB Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis | 2027-02 |
| NCT06495593University of California, San FranciscoEffects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 14 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received two intravenous (IV) infusions of matching placebo separated by 14 days in Cycle 1, followed by two infusions of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4. Each cycle was of 168 days.
Drug: Placebo
Participants two IV infusions of ocrelizumab 300 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 600 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
Drug: Ocrelizumab
Participants received two IV infusions of ocrelizumab 1000 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 1000 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 1000 mg was administered on Day 1 of Cycle 3 and a single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycle 4. Each cycle was of 168 days.
Drug: Ocrelizumab
Participants received weekly intramuscular injections of Avonex 30 microgram (mcg) in Cycle 1, followed by two infusions of OCR 300 mg separated by 14 days in Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
Drug: Avonex
Placebo matching to ocrelizumab administered as IV infision in Cycle 1 Day 1.
Ocrelizumab 300 mg was administered in cycle 1 followed by an infusion of ocrelizumab 600 mg on Day 1. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.
Also known as: RO4964913
Avonex was administered weekly intramuscular injections of 30 mcg in cycle 1 Day 1.
Also known as: Interferon-beta-alpha1
Total Number of Gadolinium-Enhancing T1 Lesions Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain
Mean of total number of gadolinium-enhancing T1 lesions observed on MRI scans of the brain at Weeks 12, 16, 20, 24 was determined using average imputation method.
Time frame: Week 12 to Week 24
Annualized Protocol Defined Relapse Rate at Week 24
Adjusted annualized relapse rate for geographical region is reported here. The relapse rate was calculated as the total number of relapses for each participant divided by the total number of patient-years.
Time frame: Week 24
Percentage of Participants Who Remained Relapse Free at Week 24
Percentage of participants who remained relapse free at week 24 were reported. Percentages have been rounded off to the first decimal.
Time frame: Week 24
Change From Baseline in Total Volume of T2 Lesions on MRI Scans of the Brain at Week 24
Change from baseline in total volume of T2 lesions on MRI scans of the brain at Week 24 was reported.
Time frame: Baseline, Week 24
Total Number of New Gadolinium-Enhancing T1 Lesions Observed by MRI Scans of the Brain
Total number of new gadolinium-enhancing T1 lesions observed by MRI scans of the brain were reported.
Time frame: Weeks 4 to Week 24
Total Number of Gadolinium-Enhancing T1 Lesions
Total number of gadolinium-enhancing T1 lesions from Week 4 to Week 24 were reported.
Time frame: Weeks 4 to Week 24
A total of 220 participants were randomized, of which 218 received study treatment. Participants took part in the study at 79 investigative sites across 18 countries from July 17, 2008, to November 08, 2023.
| Milestone | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg |
|---|---|---|---|---|
| Started | 54 | 55 | 55 | 54 |
| Completed | 48 | 46 | 43 | 46 |
| Not completed | 6 | 9 | 12 | 8 |
| Withdrew: Adverse event | 0 | 3 | 2 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Failure to return | 1 | 0 | 0 | 0 |
| Withdrew: Violation of selection criteria at entry | 0 | 0 | 1 | 0 |
| Withdrew: Refused treatment/did not cooperate | 1 | 2 | 3 | 1 |
| Withdrew: Withdrew consent | 3 | 3 | 3 | 3 |
| Withdrew: Insufficient therapeutic response | 1 | 1 | 2 | 1 |
| Withdrew: Administrative | 0 | 0 | 0 | 1 |
| Milestone | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg |
|---|---|---|---|---|
| Started | 49 | 48 | 50 | 49 |
| Completed | 35 | 32 | 30 | 35 |
| Not completed | 14 | 16 | 20 | 14 |
| Withdrew: Withdrawal by subject | 3 | 3 | 4 | 5 |
| Withdrew: Reason not provided | 8 | 10 | 8 | 7 |
| Withdrew: Lost to follow-up | 2 | 2 | 6 | 2 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Death | 1 | 1 | 1 | 0 |
| Milestone | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg |
|---|---|---|---|---|
| Started | 29 | 32 | 19 | 24 |
| Completed | 22 | 21 | 11 | 14 |
| Not completed | 7 | 11 | 8 | 10 |
| Withdrew: Reason not provided | 3 | 4 | 1 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 4 | 3 | 3 |
| Withdrew: Adverse event | 0 | 3 | 1 | 0 |
| Withdrew: Death | 2 | 0 | 2 | 2 |
Mean of total number of gadolinium-enhancing T1 lesions observed on MRI scans of the brain at Weeks 12, 16, 20, 24 was determined using average imputation method.
| lesions | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg |
|---|---|---|---|---|
| Total Number of Gadolinium-Enhancing T1 Lesions Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain | 5.6 ± 12.53 | 0.6 ± 1.52 | 0.2 ± 0.65 | 6.9 ± 16.01 |
Adjusted annualized relapse rate for geographical region is reported here. The relapse rate was calculated as the total number of relapses for each participant divided by the total number of patient-years.
| relapses per year | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg |
|---|---|---|---|---|
| Annualized Protocol Defined Relapse Rate at Week 24 | 0.557 (0.370 to 0.839) | 0.127 (0.054 to 0.299) | 0.213 (0.110 to 0.414) | 0.364 (0.220 to 0.602) |
Percentage of participants who remained relapse free at week 24 were reported. Percentages have been rounded off to the first decimal.
| percentage of participants | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg |
|---|---|---|---|---|
| Percentage of Participants Who Remained Relapse Free at Week 24 | 75.9 (64.5 to 87.3) | 85.5 (76.1 to 94.8) | 87.3 (78.5 to 96.1) | 77.8 (66.7 to 88.9) |
Change from baseline in total volume of T2 lesions on MRI scans of the brain at Week 24 was reported.
| cubic millimeter (mm^3) | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg |
|---|---|---|---|---|
| Baseline | 8950.84 ± 9776.261 | 13972.61 ± 19930.158 | 13178.30 ± 14271.383 | 13209.11 ± 17206.511 |
| Change at Week 24 | -112.31 ± 1464.206 | -878.84 ± 2756.839 | -600.89 ± 2105.964 | 1040.06 ± 4510.140 |
Total number of new gadolinium-enhancing T1 lesions observed by MRI scans of the brain were reported.
| lesions | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg |
|---|---|---|---|---|
| Total Number of New Gadolinium-Enhancing T1 Lesions Observed by MRI Scans of the Brain | 5.1 ± 11.99 | 0.8 ± 1.95 | 0.8 ± 2.16 | 6.2 ± 13.79 |
Total number of gadolinium-enhancing T1 lesions from Week 4 to Week 24 were reported.
| lesions | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg |
|---|---|---|---|---|
| Total Number of Gadolinium-Enhancing T1 Lesions | 8.7 ± 17.54 | 2.5 ± 5.10 | 1.8 ± 5.26 | 10.3 ± 22.15 |
Collected over Up to 787 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Ocrelizumab 600mg | 3/54 (5.6%) | 11/54 (20.4%) | 52/54 (96.3%) |
| Ocrelizumab 600mg/Ocrelizumab 600mg | 1/55 (1.8%) | 17/55 (30.9%) | 47/55 (85.5%) |
| Ocrelizumab 1000mg/Ocrelizumab 600mg | 3/55 (5.5%) | 16/55 (29.1%) | 45/55 (81.8%) |
| Avonex/Ocrelizumab 600 mg | 2/54 (3.7%) | 16/54 (29.6%) | 45/54 (83.3%) |
| Ocrelizumab 600 mg Open Label Extension (OLE) | 6/103 (5.8%) | 28/103 (27.2%) | 85/103 (82.5%) |
| Event | Placebo/Ocrelizumab 600mg | Ocrelizumab 600mg/Ocrelizumab 600mg | Ocrelizumab 1000mg/Ocrelizumab 600mg | Avonex/Ocrelizumab 600 mg | Ocrelizumab 600 mg Open Label Extension (OLE) |
|---|---|---|---|---|---|
| COVID-19 PNEUMONIAInfections and infestations | 3/54 | 3/55 | 0/55 | 0/54 | 6/103 |
| URINARY TRACT INFECTIONInfections and infestations | 0/54 | 0/55 | 3/55 | 0/54 | 3/103 |
| COVID-19Infections and infestations | 1/54 | 1/55 | 0/55 | 2/54 | 4/103 |
| PNEUMONIAInfections and infestations | 2/54 | 1/55 | 1/55 | 0/54 | 4/103 |
| MULTIPLE SCLEROSIS RELAPSENervous system disorders | 0/54 | 0/55 | 0/55 | 2/54 | 0/103 |
| SEPSISInfections and infestations | 1/54 | 0/55 | 1/55 | 0/54 | 2/103 |
| BACK PAINMusculoskeletal and connective tissue disorders | 1/54 | 1/55 | 1/55 | 0/54 | 2/103 |
| MULTIPLE SCLEROSIS PSEUDO RELAPSENervous system disorders | 0/54 | 0/55 | 1/55 | 1/54 | 2/103 |
| ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 1/54 | 0/55 | 0/55 | 1/54 | 2/103 |
| CARDIAC ARRESTCardiac disorders | 0/54 | 0/55 | 0/55 | 1/54 | 1/103 |
| Event | Placebo/Ocrelizumab 600mg | Ocrelizumab 600mg/Ocrelizumab 600mg | Ocrelizumab 1000mg/Ocrelizumab 600mg | Avonex/Ocrelizumab 600 mg | Ocrelizumab 600 mg Open Label Extension (OLE) |
|---|---|---|---|---|---|
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 29/54 | 25/55 | 29/55 | 20/54 | 23/103 |
| MULTIPLE SCLEROSIS RELAPSENervous system disorders | 26/54 | 19/55 | 21/55 | 29/54 | 28/103 |
| HEADACHENervous system disorders | 15/54 | 9/55 | 10/55 | 12/54 | 7/103 |
| NASOPHARYNGITISInfections and infestations | 10/54 | 15/55 | 12/55 | 9/54 | 20/103 |
| URINARY TRACT INFECTIONInfections and infestations | 14/54 | 10/55 | 15/55 | 10/54 | 23/103 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 10/54 | 14/55 | 11/55 | 7/54 | 15/103 |
| COVID-19Infections and infestations | 12/54 | 7/55 | 5/55 | 2/54 | 26/103 |
| INFLUENZA LIKE ILLNESSGeneral disorders | 1/54 | 2/55 | 2/55 | 11/54 | 3/103 |
| FATIGUEGeneral disorders | 5/54 | 7/55 | 11/55 | 4/54 | 8/103 |
| BACK PAINMusculoskeletal and connective tissue disorders | 9/54 | 5/55 | 4/55 | 7/54 | 6/103 |
The safety population included all participants who received any study drug and underwent at least one assessment of safety.
| Age, Continuous(years) | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg | Total |
|---|---|---|---|---|---|
| Mean | 38.0 ± 8.8 | 35.6 ± 8.5 | 38.5 ± 8.7 | 38.1 ± 9.3 | 37.6 ± 8.8 |
| Sex: Female, Male(Participants) | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg | Total |
|---|---|---|---|---|---|
| Female | 36 | 35 | 38 | 32 | 141 |
| Male | 18 | 20 | 17 | 22 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 6 | 7 | 7 | 26 |
| Not Hispanic or Latino | 48 | 49 | 48 | 47 | 192 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo / Ocrelizumab 600 mg | Ocrelizumab 600 mg / Ocrelizumab 600 mg | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg | Avonex / Ocrelizumab 600 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 3 | 2 | 1 | 6 |
| White | 52 | 51 | 53 | 53 | 209 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
Ran from Jul 2008 to primary completion in Mar 2012, 43 months.
Results were first posted in May 2017, 5 years 2 months after primary completion. A results delay was requested in Mar 2013.
Of 25 phase 2 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 43 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab
Multiple Sclerosis, Relapsing-Remitting →